Overview

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Interferon-alpha
Ledipasvir
Peginterferon alfa-2a
Ribavirin